Story perspectives

AstraZeneca's Baxdrostat: Hope for Resistant Hypertension Treatment

9/1/2025

Summary

Story summary

AstraZeneca's Baxdrostat shows potential for treating resistant hypertension, with nearly 40% of trial participants achieving healthy blood pressure after 12 weeks.
The drug lowers aldosterone production, targeting a major cause of hypertension, potentially benefiting 500 million people worldwide.
Results were shared at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine.
Mild side effects were noted, and approval could lead to availability by 2026, advancing hypertension treatment.

1 of 1

Story summary

AstraZeneca's Baxdrostat shows potential for treating resistant hypertension, with nearly 40% of trial participants achieving healthy blood pressure after 12 weeks.
The drug lowers aldosterone production, targeting a major cause of hypertension, potentially benefiting 500 million people worldwide.
Results were shared at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine.
Mild side effects were noted, and approval could lead to availability by 2026, advancing hypertension treatment.